- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Firm offers health check on the Web
Greenstone Healthcare Solutions, the Kalamazoo, MI-based disease management subsidiary of Pharmacia & Upjohn, launched a free, confidential health-risk assessment on the World Wide Web.
Greenstone Healthcare Solutions, the Kalamazoo, MI-based disease management subsidiary of Pharmacia & Upjohn, launched a free, confidential health-risk assessment on the World Wide Web.
The You First⢠Health Risk Assessment uses a browser's answers to questions about family history, health habits and lifestyle behaviors to create a personal report that includes recommendations to improve health and minimize potential problems. Through statistical analysis, a person's lifestyle risks, such as smoking, obesity and not wearing seat belts, are evaluated against documented outcomes associated with those risks.
Respondents receive a report that uses charts and graphs to depict their overall health risk along a continuum from "very low" risk to "very high." The questionnaire takes about five minutes to complete and is located at http://www.youfirst.com.
Greenstone will customize access to its health risk assessment for MultiPlan Inc., a preferred provider organization with more than 20 million lives in the United States. The company also plans to sell the product as an on-line product or in printed format to other organizations.
Information on Greenstone and disease management is located at the company's Web site at http://www.ghsnet.com. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
